drugset / Trial / NCT03269071

Neural Stem Cell Transplantation in Multiple Sclerosis Patients

NCT03269071 ↗

Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase I study evaluating the feasibility, safety and tolerability of intrathecally administered human Neural Stem Cells (hNSCs), at an escalating dose ranging from 0.7x10\^6±10% cells to 5.7x10\^6±10% cells/kg of body weight, in patients affected by Progressive Multiple Sclerosis

Timeline

Start
2017-05-17
Primary completion
2021-07-31
Completion
2021-07-31

Outcome

Met primary endpoint

paper The safety primary outcome was reached, with no severe adverse reactions related to hfNPCs at 2-year follow-up PMID 36624312 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject human fetal-derived Neural Stem Cells Cell therapy 700000 cells/kg Intrathecal
Subject human fetal-derived Neural Stem Cells Cell therapy 1.4e+06 cells/kg Intrathecal
Subject human fetal-derived Neural Stem Cells Cell therapy 2.8e+06 cells/kg Intrathecal
Subject human fetal-derived Neural Stem Cells Cell therapy 5.7e+06 cells/kg Intrathecal

Indications